<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00199290</url>
  </required_header>
  <id_info>
    <org_study_id>KCB-1D-02</org_study_id>
    <nct_id>NCT00199290</nct_id>
  </id_info>
  <brief_title>A Phase2 Clinical Trial of Trafermin in Patients With Marginal Periodontitis in Japan</brief_title>
  <official_title>A Phase 2, Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and the Safety of Trafermin in Patients With Marginal Periodontitis in Japan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaken Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaken Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the efficacy and the safety of Trafermin(recombinant human
      basic fibroblast growth factor: rhbFGF) in Japanese patients with marginal periodontitis, in
      order to verify the superiority of Trafermin to placebo, and to determine the recommended
      therapeutic dose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rate of increase in alveolar bone height</measure>
    <time_frame>36 weeks after administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical attachment level regained</measure>
    <time_frame>36 weeks after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time course of increase rate in alveolar bone height</measure>
    <time_frame>within 36 weeks after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time course of clinical attachment level regained</measure>
    <time_frame>within 36 weeks after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurrence and level of adverse reaction</measure>
    <time_frame>within 36 weeks after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum anti-Trafermin antibody level</measure>
    <time_frame>within 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum Trafermin level</measure>
    <time_frame>within 24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">267</enrollment>
  <condition>Periodontitis</condition>
  <arm_group>
    <arm_group_label>P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>L</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low dose (0.2 %)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>medium dose (0.3 %)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose (0.4 %)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trafermin (genetical recombination)</intervention_name>
    <arm_group_label>P</arm_group_label>
    <arm_group_label>L</arm_group_label>
    <arm_group_label>M</arm_group_label>
    <arm_group_label>H</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The patient with marginal periodontitis intend to conduct a flap operation(modified Widman)
        must meet the following criteria:

          -  Alveolar bone defect diagnosed by radiography.

          -  Mobility of teeth must be &lt;=2 and the width of attached gingiva is suitable for
             GTR(guided tissue regeneration) method.

          -  Males and females, &gt;=20 years of age.

        Exclusion Criteria:

        Patients will be excluded from the study if any of the following conditions are present:

          -  Concomitant administration of adrenal cortical steroid within 4weeks of treatment in
             the trial.

          -  Current or previous history of gingival overgrowth by drugs.

          -  Current or previous history of cancer or malignant tumour.

          -  Presence of diabetes mellitus(HbA1c&gt;=6.5%)

          -  Presence of malnutrition(serum albumin&lt;=2g/dL)

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Makoto Tamura, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Kaken Pharmaceutical Co.,Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaken Investigational Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>464-8651</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaken Investigational Site</name>
      <address>
        <city>Matsudo</city>
        <state>Chiba</state>
        <zip>271-8587</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaken Investigational Site</name>
      <address>
        <city>Kitakyusyu</city>
        <state>Fukuoka</state>
        <zip>803-8580</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaken Investigational Site</name>
      <address>
        <city>Mizuho</city>
        <state>Gifu</state>
        <zip>501-0296</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaken Investigational Site</name>
      <address>
        <city>Ishikari-gun</city>
        <state>Hokkaido</state>
        <zip>061-0293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaken Investigational Site</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaken Investigational Site</name>
      <address>
        <city>Morioka</city>
        <state>Iwate</state>
        <zip>020-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaken Investigational Site</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>230-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaken Investigational Site</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>980-8575</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaken Investigational Site</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaken Investigational Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8549</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaken Investigational Site</name>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <zip>101-8310</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaken Investigational Site</name>
      <address>
        <city>Machida</city>
        <state>Tokyo</state>
        <zip>194-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaken Investigational Site</name>
      <address>
        <city>Sinjyuku-ku</city>
        <state>Tokyo</state>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaken Investigational Site</name>
      <address>
        <city>Chiba</city>
        <zip>261-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaken Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaken Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>814-0193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaken Investigational Site</name>
      <address>
        <city>Hiroshima</city>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaken Investigational Site</name>
      <address>
        <city>Kagoshima</city>
        <zip>890-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaken Investigational Site</name>
      <address>
        <city>Nagasaki</city>
        <zip>852-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaken Investigational Site</name>
      <address>
        <city>Niigata</city>
        <zip>951-8122</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaken Investigational Site</name>
      <address>
        <city>Okayama</city>
        <zip>700-8525</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaken Investigational Site</name>
      <address>
        <city>Tokushima</city>
        <zip>770-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>February 1, 2008</last_update_submitted>
  <last_update_submitted_qc>February 1, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2008</last_update_posted>
  <keyword>Trafermin</keyword>
  <keyword>Periodontitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

